Innate Pharma (IPHA) Short term Debt (2017 - 2025)

Innate Pharma (IPHA) has reported Short term Debt for 9 consecutive years, with $10.0 million the latest figure, recorded in Q4 2025.

• Quarterly Short term Debt rose 1.07% year-over-year to $10.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.0 million (up 1.07% YoY) and the FY2025 annual result came in at $10.0 million, up 1.07% from the prior year.
• Short term Debt fell to $10.0 million in Q4 2025 per IPHA's latest filing, from $10.2 million in the prior quarter.
• Over the last five years, Short term Debt for IPHA reached as high as $35.1 million in Q2 2022 and fell as low as $2.3 million in Q2 2021.
• A 5-year average of $13.1 million and a median of $10.1 million in 2024 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2021 — Short term Debt plunged 99.89% — and 2022, when it surged 1429.55%.
• Year by year, Short term Debt stood at $35.0 million in 2021, then sank by 93.16% to $2.4 million in 2022, then soared by 325.12% to $10.2 million in 2023, then dropped by 2.54% to $9.9 million in 2024, then climbed by 1.07% to $10.0 million in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $10.0 million, $10.2 million, and $9.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.